301 related articles for article (PubMed ID: 24588314)
1. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.
Güler M; Capkın M; Simşek A; Bilak S; Bilgin B; Hakim Reyhan A; Fırat M
Curr Eye Res; 2014 Oct; 39(10):989-93. PubMed ID: 24588314
[TBL] [Abstract][Full Text] [Related]
2. Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.
Arslan GD; Guven D; Alkan AA; Kacar H; Demir M
Cutan Ocul Toxicol; 2019 Dec; 38(4):344-348. PubMed ID: 31092017
[No Abstract] [Full Text] [Related]
3. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
Omay E; Elgin U; Sen E; Yilmazbas P
Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
[TBL] [Abstract][Full Text] [Related]
4. Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab-triamcinolone acetate combination.
Alkin Z; Perente I; Altan C; Konstantinidis A; Ozkaya A; Yuksel K; Yazici AT; Demirok A
Eur J Ophthalmol; 2013; 23(4):504-9. PubMed ID: 23640509
[TBL] [Abstract][Full Text] [Related]
5. The short-term effects of intravitreal bevacizumab injection on intraocular pressure, cornea, iridocorneal angle, and anterior chamber.
Gumus G; Berhuni M; Ozturkmen C
Ther Adv Ophthalmol; 2022; 14():25158414221133772. PubMed ID: 36340047
[TBL] [Abstract][Full Text] [Related]
6. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
Fuest M; Kotliar K; Walter P; Plange N
Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of anterior segment parameter changes using the Pentacam after uneventful phacoemulsification.
Doganay S; Bozgul Firat P; Emre S; Yologlu S
Acta Ophthalmol; 2010 Aug; 88(5):601-6. PubMed ID: 19053959
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of intraocular pressure change and anterior segment parameters after intravitreal bevacizumab injection - Cannula size matters.
Hamidi NA; Güneş İB; Baykara M
Saudi J Ophthalmol; 2020; 34(4):247-250. PubMed ID: 34527866
[TBL] [Abstract][Full Text] [Related]
9. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections.
Lemos V; Cabugueira A; Noronha M; Abegão Pinto L; Reina M; Branco J; Gomes T
Ophthalmologica; 2015; 233(3-4):162-8. PubMed ID: 25791262
[TBL] [Abstract][Full Text] [Related]
10. Anterior chamber depth, iridocorneal angle width, and intraocular pressure changes after uneventful phacoemulsification in eyes without glaucoma and with open iridocorneal angles.
Altan C; Bayraktar S; Altan T; Eren H; Yilmaz OF
J Cataract Refract Surg; 2004 Apr; 30(4):832-8. PubMed ID: 15093646
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
12. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
[TBL] [Abstract][Full Text] [Related]
13. The ocular pulse amplitude at different intraocular pressure: a prospective study.
Knecht PB; Bosch MM; Michels S; Mannhardt S; Schmid U; Bosch MA; Menke MN
Acta Ophthalmol; 2011 Aug; 89(5):e466-71. PubMed ID: 21401909
[TBL] [Abstract][Full Text] [Related]
14. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
15. Effects of hemodialysis on corneal and anterior chamber morphometry and intraocular pressure in patients with end-stage renal disease.
Caglayan M; Kosekahya P; Takmaz T; Altunoglu A; Ayan B; Atilgan CU; Uysal BS
Arq Bras Oftalmol; 2017 Jun; 80(3):176-180. PubMed ID: 28832743
[TBL] [Abstract][Full Text] [Related]
16. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection.
Ishibashi S; Tawara A; Sohma R; Kubota T; Toh N
Arch Ophthalmol; 2010 Dec; 128(12):1539-45. PubMed ID: 21149776
[TBL] [Abstract][Full Text] [Related]
17. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Kim JE; Mantravadi AV; Hur EY; Covert DJ
Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
[TBL] [Abstract][Full Text] [Related]
18. Comprasion of ICare rebound tonometer and Goldmann applanation tonometer in high myopia.
Cagatay HH; Ekinci M; Yazar Z; Gokce G; Ceylan E
ScientificWorldJournal; 2014; 2014():869460. PubMed ID: 25379549
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
20. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
